A legacy that inspires the Future.
From the first guidewire to the first drug-eluting stent, Cordis has been at the heart of cardiovascular innovation for nearly 70 years. Today, Cordis drives transformation through internal development, Cordis-X partnerships, and strategic acquisitions—powered by a global footprint and deep operational expertise. With a focus on better clinical outcomes, customer-centered service, and impactful education, Cordis will Go Beyond to relentlessly pursue its mission to transform cardiovascular care.
Innovating and Delivering New Technologies
Cordis is proud to have completed the acquisition of MedAlliance and its novel SELUTION SLR™ Drug-Eluting Balloon (DEB). Using breakthrough proprietary technology, MedAlliance has found a unique solution to the challenge of controlled and sustained sirolimus release with the SELUTION SLR™ DEB. Cordis and MedAlliance combined are committed to accelerating the development and commercialization of innovative cardiovascular interventional products around the world.
The SELUTION SLRTM Drug-Eluting Balloon is not approved for sale in every country. Please contact your local representative for additional information
Need Help?
We’re here with the support and information to help you make the right decision for your patients.